Vice Chairman for Research, Department of Surgery, North Shore University Hospital
and Long Island Jewish Medical Center
Head, Center for Translational Research, The Feinstein Institute for Medical Research
Investigator and Director of Laboratory of Surgical Research, The Feinstein Institute for Medical Research
Professor of Surgery and Molecular Medicine, Hofstra North Shore-LIJ School of Medicine
Phone: (516) 562-3411
Ping Wang, MD, is vice chairman for research in the department of surgery at North Shore University Hospital and Long Island Jewish Medical Center. He is also professor of surgery and molecular medicine at Hofstra North Shore-LIJ School of Medicine and an investigator and head of the Center for Translational Research in The Feinstein Institute for Medical Research.
Prior to joining the department of surgery at North Shore University Hospital and Long Island Jewish Medical Center, Dr. Wang held positions of associate professor in the department of surgery at Brown University School of Medicine and professor of surgery (with tenure), professor of pathology, physiology and biophysics at University of Alabama at Birmingham (UAB).
In 2002, Dr. Wang became professor of surgery at Albert Einstein College of Medicine and chief of the division of surgical research at North Shore University Hospital and Long Island Jewish Medical Center. Dr. Wang is a member of various societies, including American Physiological Society, Shock Society, Society of Critical Care Medicine, Surgical Infection Society, Society for Leukocyte Biology, Association for Academic Surgery, American Heart Association, American Association for the Advancement of Science and NY Academy of Science.
Dr. Wang is also the editor-in-chief of International Journal of Clinical and Experimental Medicine. He serves as the editorial board member for: Shock, Int J Mol Med, Digestive Surgery, Frontiers of Medicine, International Journal of Clinical and Experimental Pathology, Experimental and Therapeutic Medicine, American Journal of Translational Research, Hepatic Medicine, and International Journal of Burns and Trauma. He served as guest reviewer for: Am J Physiol, Am J Respir Crit Care Med, Arch Surg, Atherosclerosis, Biochim Biophys Acta, Cardiovasc Res, Crit Care Med, Free Radical Bio Med, Horm Metab Res, J Surg Res, Mol Cell Biochem, Nat Protoc, Hypertension, Peptides, Surg Infec, Life Sciences, J Hepatol, Physiol Genomics, Exp Biol Med, Front Biosci, J Leukoc Biol, J Endocrinol, Infect Immun, J Immunol, Infect Immun, J Pharmacol Exp Ther, Nat Protoc. Reviewer for: US Army Hemorrhage Control Research Program Review. Dr. Wang is also a co-founder of TheraSource LLC. He has been was a member of various NIH Study Sections and VA Surgery Study Section.
In 1995, Dr. Wang received the NIH FIRST Award and has continually been funded by the NIH. The Laboratory of Surgical Research was originated in 2002 at the Department of Surgery, North Shore University Hospital and Long Island Jewish Medical Center. Since then, the lab has grown extensively and currently has more than 20 team members ranging from associate investigator/professor to PhD students.
In addition, Dr. Wang is a mentor for junior faculty, postdoctoral fellows and graduate students within his lab and for other individuals at The Feinstein Institute for Medical Research, as well as other institutions. A number of the scientists and postdoctoral fellows from the lab received awards such as the New Investigator Award, Annual Scientific Award and travel awards. Dr. Wang and colleagues have published more than 340 articles in peer-reviewed journals.
Sepsis often occurs in many critical illnesses and defined as a systemic inflammatory response associated with a proven or suspected infection. Despite advances in the management of sepsis, a large number of patients die of the ensuing septic shock and multiple organ failure as well as circulatory collapse due to blood loss with progressive cell and organ damage. Dr. Wang’s long-term goal is to develop better therapies to prevent progression of these processes. Currently, several potential drug candidates are already at the preclinical stage to further develop them as therapeutic agents for treating sepsis and other organ injuries including hemorrhagic shock, ischemia and reperfusion injury, radiation injury and focal cerebral ischemia (stroke).
Recently Dr. Wang identified a novel inflammatory mediator, cold inducible RNA-binding protein (CIRP) in animal models of hemorrhage and sepsis as well as in the blood of individuals admitted to the surgical intensive care unit with hemorrhagic shock. In rodents, blockade of CIRP using antisera to CIRP attenuated inflammatory cytokine release and mortality after hemorrhage and sepsis. The activity of extracellular CIRP is mediated through the Toll-like receptor 4 interactions and CIRP is confirmed as a damage associated molecular pattern molecule that promotes inflammation in shock and sepsis. Studies are underway to generate inhibitors of CIRP in an effort to develop them as therapy for hemorrhagic shock and other injury conditions. We are also currently enrolling patients from our surgical intensive care unit to correlate the blood levels of CIRP to clinical parameters of hemorrhagic shock and patient outcome.
After the discovery that CIRP as a novel mediator of shock and sepsis, we extended our studies to examine its role in neuroinflammation. We demonstrated that CIRP plays an important role in stroke-associated neuroinflammation and brain injury. We also showed that CIRP is an important mediator in alcohol-induced brain inflammation. Studies are ongoing to examine additional functions of CIRP in brain related injuries.
Milk fat globule-EGF Factor 8 (MFG-E8) is a glycoprotein secreted by activated macrophages and immature dendritic cells to promote the engulfment of apoptotic cells by working as a bridging molecule between those cells and phagocytes. Dr. Wang has shown that MFG-E8 is downregulated in sepsis and that the administration of recombinant MFG-E8 during sepsis provided beneficial effects, including attenuating pro-inflammatory response, increasing apoptotic cell clearance, and improving survival in sepsis. MFG-E8 treatment reduces acute lung injury caused by an intestinal ischemia and reperfusion injury model. Studies are being done to establish the efficacy and optimal dosage of recombinant human MFG-E8 in an attempt to develop it as a therapy for sepsis and other organ injury conditions. In addition, a peptide derived from MFG-E8 has shown to be protective in sepsis and preclinical studies are now ongoing to determine the efficacy of this peptide. Currently we are conducting preclinical studies to examine the efficacy of recombinant human MFG-E8 as a treatment for chronic inflammatory diseases.
Adrenomedullin (AM) is a potent vasoactive peptide. While AM is increased in sepsis and other organ injury conditions, AM is hyporesponsive due to the lack of its binding protein, AMBP-1. Dr. Wang has shown that treatment with AM/AMBP-1 is beneficial in sepsis, gut, renal, hepatic and cerebral ischemia-reperfusion injuries in rodent models. Pharmacokinetic and pharmacotoxicity studies are currently underway to develop AM/AMBP-1 as therapy for sepsis and other organ injuries. We are extending these studies in non-rodent species to file an investigational drug (IND) application to the FDA for initiating clinical trials in various injury conditions.
Ghrelin, a stomach derived peptide, is reduced in sepsis and other organ injury conditions. The downregulation of ghrelin activates sympathostimulatory nuclei in the brain, increasing norepinephrine release from the sympathetic nerve fibers in the gut, resulting in upregulation of proinflammatory cytokines and subsequent injuries to the liver and other organs (the brain-gut-liver axis paradigm). He has also shown that treatment with ghrelin downregulates organ injury in renal ischemia-reperfusion injury, radiation combined injury, and focal cerebral ischemia. Dr. Wang’s results showed that ghrelin acts via the vagus nerve to downregulate proinflammatory responses in these injury conditions. Preclinical studies are ongoing to develop ghrelin as a radiation mitigator for patients suffering from nuclear disaster related complications.
Monowar Aziz, PhD
Research: Immunology and Inflammation
Alexandra Bolognese, MD
Elmezzi Scholar, PhD Candidate
Research: CIRP and Inflammation
Max Brenner, MD, PhD
Research: Chronic Inflammatory Diseases
Cindy Cen, MD
Surgical Resident (Research)
Research: MFG-E8 and Inflammation
Wayne Chaung, PhD
Research: Inflammatory Mediators
Kane Genser, MD
Surgical Resident (Research)
Research: Hemorrhagic Shock
Laura Hansen, MD
Surgical Resident (Research)
Research: Neonatal Sepsis
Louie B. Hendricks, MD
Surgical Resident (Research)
Research: Neutrophil Activation
Yohei Hirano, MD
Post Doctoral Research Fellow
Research: Pathophysiology of Inflammation
Maria Ma, MD
Research: Drug Discovery and Development
Mahendar Ochani, MD
Research: Animal Models of Human Diseases
Jose M. Prince, MD
Research: Necrotizing Colitis and Sepsis
Xiaoling Qiang, MD, PhD
Research: Inflammatory Mediators
Madeline Ann Quinn
Research: Laboratory Manager
Archna Sharma, PhD
Research: Cellular Immunity and Inflammation
Asha Varghese, PhD
Research: Sepsis and Inflammation
Wendy Wang, MD
Research: Inflammation and Drug Development
Weng-Lang Yang, PhD
Associate Investigator/Associate Professor
Research: Inflammation and Signaling Pathways
Fangming Zhang, MD, PhD
Research: Inflammatory Diseases
Mian Zhou, MD
Research: Sepsis, Hemorrhage, Ischemia/Reperfusion Injury
Changwei Medical College, China
Field of Study: Medicine
Third Medical University, China
Field of Study: Surgery
University of Washington, Seattle, WA
Field of Study: Pharmacology
Brown University, Providence, RI
Field of Study: Honorary MA
1995-2000 NIH FIRST Award (R29)
1996-2001 NIH Independent Scientist Award (K02)
1998 Master of Arts Degree ad eundem, Brown University
2002 Annual Scientific Award, Society of Critical Care Medicine
2011 Annual Scientific Award, Society of Critical Care Medicine
- Qiang X*, Yang W-L*, Wu R, Zhou M, Jacob A, Dong W, Kuncewitch M, Ji Y, Yang H, Wang H, Fujita J, Nicastro J, Coppa GF, Tracey KJ, Wang P: “Cold-inducible RNA-binding protein (CIRP) triggers inflammatory responses in hemorrhagic shock and sepsis.” Nat Med 19:1489-1495, 2013. *equal contribution
- Zhou M, Wang CW, Yang W-L, Wang P: “Microglial CD14 activated by iNOS contributes to neuroinflammation in cerebral ischemia.” Brain Res 1506:105-114, 2013.
- Matsuo S, Yang W-L Aziz M, Jacob A, Wang P: “Cycliac arginine-glycine-aspartate attenuates acute lung injury in mice after intestinal ischemia-reperfusion.” Crit Care 17:R19, 2013 (12 pages).
- Aziz M, Jacob A, Yang W-L, Matsuda A, Wang P: “Current trends in inflammatory and immunomodulatory mediators in sepsis.” J Leukoc Biol 93:329-342, 2013.
- Matsuda A, Yang W-L, Jacob A, Aziz M, Matsuo S, Matstani T, Uchida E, Wang P: “FK866, a visfatin inhibitor, protects against acute lung injury after intestinal ischemia-reperfusion in mice via NF-kB pathway.” Ann Surg 259: 1007-1017, 2014.
- Matsuo S, Yang W-L, Aziz M, Kameoka S, Wang P: “Fatty acid synthase inhibitor C75 ameliorates experimental colitis.” Mol Med 20:1-9, 2014.
- Aziz M, Yang W-L, Matsuo S, Sharma A, Zhou M, Wang P: “Upregulation of GRAIL is associated with impaired CD4 T-cell proliferation in sepsis.” J Immunol 192:2305-2314, 2014.
- Zhou M, Yang W-L, Ji Y, Qiang X, Wang P: “Cold-inducible RNA-binding protein mediates neuroinflammation in cerebral ischemia.” Biochim Biophys Acta 1840:2253-2261, 2014.
- Khader A, Yang W-L, Kuncewitch M, Jacob A, Prince JM, Asirvatham JR, Nicastro J, Coppa GF, Wang P: “Sirtuin 1 activation stimulates mitochondrial biogenesis and attenuates renal injury after ischemia-reperfusion.” Transplantation 98:148-156, 2014.
- Sharma A, Matsuo S, Yang W-L, Wang Z, Wang P: “Receptor-interacting protein kinase 3 deficiency inhibits immune cell infiltration and attenuates organ injury in sepsis.” Crit Care 18:R142, 2014 (13 pages).
- Wang P (Editor): “MFG-E8 and Inflammation”, Springer, 2014 (198 pages).
- Aziz M, Jacob A, Wang P: “Revising caspases in sepsis.” Cell Death & Disease 5:e1526, 2014 (12 pages).
- Khan MM, Yang W-L, Wang P: “Endoplasmic reticulum stress in sepsis.” Shock 44:294-304, 2015.
- Cheyuo C, Aziz M, Yang W-L, Jacob A, Zhou M, Wang P: “Milk fat globule-EGF factor VIII attenuates CNS injury by promoting neural stem cell proliferation and migration after cerebral ischemia.” PLoS One 10:e0122833, 2015 (17 pages).
- Zhang Y, Brenner M, Yang WL, Wang P: “Recombinant human MFG-E8 ameliorates colonic damage in DSS- and TNBS-induced colitis in mice.” Lab Invest 95:480-490, 2015.
- Aziz M, Yang W-L, Corbo LM, Chaung WW, Matsuo S, Wang P: “MFG-E8 inhibits neutrophil migration via αvβ3-integrin-dependent MAP kinase activation.” Int J Mol Med 36:18-28, 2015.
- Sharma A, Yang W-L, Matsuo S, Wang P: “Differential alterations of tissue T-cell subsets after sepsis.” Immunol Lett 168:41-50, 2015.
- Godwin A, Sharma S, Yang W-L, Wang Z, Nicastro J, Coppa GF, Wang P: “Receptor-interacting protein kinase 3 deficiency delays cutaneous wound healing.” PLoS One 10:e0140514, 2015 (17 pages).
- Giangola M, Yang W-L, Rajayer S, Kuncewitch M, Molmenti E, Nicastro J, Coppa GF, Wang P: “Growth arrest-specific protein 6 protects against renal ischemia-reperfusion injury.” J Surg Res 2015 (in press).
- Idrovo J-P, Yang W-L, Jacob A, Corbo L, Nicastro J, Coppa GF, Wang P: “Inhibition of lipogenesis reduces inflammation and injury in sepsis.” J Surg Res 2015 (in press).
- Kuncewitch M, Yang W-L, Jacob A, Khader A, Giangola M, Nicastro J, Coppa GF, Wang P: “Inhibition of fatty acid synthase with C75 reduces organ injury after hemorrhagic shock.” Surgery 2015 (in press).
- Hansen LW, Khader A, Yang W-L, Prince JM, Nicastro JM, Coppa GF, Wang P: “Sirtuin 1 activator srt1720 protects against organ injury induced by intestinal ischemia-reperfusion.” Shock 2015 (in press).
- Nikhil M, Yang W-L, Khan MM, Zhang F, Marambaud P, Nicastro JM, Coppa GF, Wang P: “Stimulation of brain AMP-activated protein kinase attenuates inflammation and acute lung injury in sepsis.” Mol Med 2015 (in press).
- Cen C, Aziz M, Yang W-L, Nicastro J, Coppa GF, Wang P: “MFG-E8 attenuates IL-17 expression in sepsis by modulating STAT3 activation.” Surgery 2015 (in press).
- Wang E, Qiang X, Li J, Zhu S, Wang P: “The in vitro immune-modulating properties of a sweat gland-derived anti-microbial peptide dermcidin.” Shock 2015 (in press).
- Yang W-L, Sharma A, Zhang F, Matsuo S, Wang Z, Wang H, Wang P: “Milk fat globule epidermal growth factor-factor 8-derived peptide (MSP68) attenuates organ injury and improves survival in sepsis.” Crit Care 2015 (in press).